DSGN

Design Therapeutics, Inc. (DSGN) - Q1 2026 Filing Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended March 31, 2026. Design Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing GeneTAC® molecules to treat diseases caused by inherited nucleotide repeat expansion mutations. The company is classified as an emerging growth company and a smaller reporting company. As of April 23, 2026, there were 62,456,974 shares of common stock outstanding.

Key Financial Metrics

Material Changes vs. Prior Period

• Operating Expenses: Total operating expenses decreased by $0.7 million compared to Q1 2025. R&D expenses declined by $1.0 million, primarily due to reduced costs in Friedreich ataxia (FA) and Fuchs endothelial corneal dystrophy (FECD) programs, offset by the initiation of clinical development costs for the myotonic dystrophy type-1 (DM1) program.
• Financing Activity: The company raised approximately $19.9 million in net proceeds through its At-The-Market (ATM) offering program during Q1 2026, issuing 2,006,550 shares. No ATM sales occurred in Q1 2025.
• Investment Portfolio: Cash and investment securities increased by $3.0 million from the prior quarter end, driven by the ATM proceeds and interest income, partially offset by operating cash burn.
• Lease Amendment: In January 2026, the company amended its lease agreement, extending the term through December 2029 and reducing base rent. This resulted in a $1.3 million increase in right-of-use assets and operating lease liabilities.

Guidance, Outlook, and Risks

Outlook and Clinical Progress:

• Friedreich Ataxia (DT-216P2): The FDA lifted a clinical hold in December 2025. The company is conducting the RESTORE-FA Phase 1/2 trial and anticipates providing an update on frataxin levels in the second half of 2026.
• FECD (DT-168): A Phase 2 biomarker trial is ongoing, with data anticipated in the second half of 2026.
• DM1 (DT-818): Regulatory clearance was obtained in late 2025. Dosing of DM1 patients in a Phase 1 MAD trial is planned for the first half of 2026, with results expected in 2027.
• Liquidity: Management believes current cash and investment resources ($222.8 million) are sufficient to fund operations for more than 12 months from the filing date.

Risks and Contingencies:

• Regulatory Uncertainty: The company faces risks related to the FDA's review process, including potential delays or additional data requirements. The recent lifting of the clinical hold on DT-216P2 was a critical milestone.
• Capital Requirements: The company has incurred net losses since inception and expects to continue doing so. Substantial additional capital will be required to complete development and commercialization.
• Third-Party Reliance: The company relies on third parties for manufacturing and clinical trials. Supply chain disruptions or vendor failures could delay development.
• Intellectual Property: Success depends on obtaining and maintaining patent protection, which is subject to legal challenges and changes in patent law.

Investor Verification Checklist

• Verify the timeline for the RESTORE-FA Phase 1/2 trial data readout (expected H2 2026) and the initiation of the DM1 Phase 1 patient dosing (expected H1 2026).
• Monitor the company's cash burn rate and the remaining runway relative to the $222.8 million liquidity position.
• Review the status of the ATM offering program and any future equity dilution risks associated with raising additional capital.
• Assess the impact of the January 2026 lease amendment on future operating costs and cash flow obligations.
• Track regulatory communications regarding the DT-216P2 program following the lifting of the clinical hold in December 2025.